Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;72(4):489-497.
doi: 10.1002/acr.23879.

How Do Glucocorticoids Used in Rheumatic Disease Affect Body Weight? A Narrative Review of the Evidence

Catharine Morgan  1 , Ruth E Costello  2 , David W Ray  3 , William G Dixon  2
Affiliations
Review

How Do Glucocorticoids Used in Rheumatic Disease Affect Body Weight? A Narrative Review of the Evidence

Catharine Morgan et al. Arthritis Care Res (Hoboken). 2020 Apr.

Abstract

Glucocorticoids (GCs) are widely used to effectively treat inflammatory disease, but GCs have a number of recognized side effects. Patients and clinicians view these side effects differently, with clinicians most concerned with serious side effects such as osteoporosis and diabetes mellitus. Consequently, these side effects are well researched with clinical guidelines and recommendations. A side effect of particular concern to patients is weight gain, but this topic has not been well researched, and consequently clinicians find it difficult to provide patients with accurate information about the potential of weight gain. The aim of this review is to provide an overview of GC use specifically in rheumatic disease, patient views on GC therapy, and GC-induced weight gain. We will discuss the evidence, including the extent and the impact of weight gain on the patient, and highlight areas that warrant further investigation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Impact of glucocorticoids on body composition.
See this image and copyright information in PMC

References

    1. Hench PS, Kendall EC. The effect of a hormone of the adrenal cortex (17‐hydroxy‐11‐dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949;24:181–97. - PubMed
    1. Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, et al. EULAR evidence‐based and consensus‐based recommendations on the management of medium to high‐dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72:1905–13. - PubMed
    1. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, et al. EULAR evidence‐based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560–7. - PMC - PubMed
    1. Herxheimer A. Communicating with patients about harms and risks. PLoS Med 2005;2:e42. - PMC - PubMed
    1. Van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom‐Bakkers MA, Buttgereit F, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010;69:1015–21. - PubMed

Publication types

MeSH terms

Substances